Abbott Laboratories Gets Regulatory Authorization for Dual Glucose-Ketone Sensor

MT newswire2026/08/25 19:22

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

03:22 PM EDT, 08/25/2026 (MT Newswires) -- Abbott Laboratories (ABT) secured US Food and Drug Administration authorization for its dual glucose-ketone sensing wearable device. The Libre Duo 10 Day system can track glucose levels and alert people with diabetes of rising ketones that could lead to a diabetic ketoacidosis emergency, Abbott said Tuesday in a statement. The company plans to launch the device in the US later this year. Price: 116.24, Change: -0.43, Percent Change: -0.37

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to media reports, OpenAI CFO Sarah Friar stated that the company's enterprise business has performed "very strongly" recently; OpenAI's overall annualized revenue run rate in July increased by 20% compared to the previous month, with enterprise business up 32% month-on-month, outpacing the growth of personal consumer business.

华尔街见闻•2026/09/08 20:46

Apnimed Q2 FY26 net income swings to USD 125.94 million; revenue falls 29.38% to USD 12.08 million

Reuters•2026/09/08 20:39

Adobe names Anil Chakravarthy CEO effective Dec. 1, 2026

Reuters•2026/09/08 20:39

Cytokinetics EVP R&D Malik Fady Ibraham disposes of 3,500 common shares for $264,110

Reuters•2026/09/08 20:39